Evotec’s AGM Prepares for Board Expansion and Dilution Risk as $100 Million Tubulis Gain Offers Counterweight

Evotec shareholders are heading into a pivotal annual meeting in Hamburg on June 11 with a packed agenda that blends governance overhaul, potential capital dilution, and the first concrete financial upside from the company’s stake in a biotech acquisition. The drug discovery group’s stock settled the week at €5.25, up 3% on Friday but still 30% below its 52-week high of €7.54, reflecting the mixed signals emanating from both the boardroom and the income statement.

The supervisory board is set to expand from six to seven members, with Dieter Weinand nominated for the chair and Dr. Wolfgang Hofmann standing as an independent candidate. More contentious for existing shareholders is the proposed Performance Share Plan 2026, which would authorise a capital increase of up to €10 million and awards covering as many as 10 million shares — equivalent to a potential dilution of roughly 5.6% on the current 177.9 million outstanding shares. No opposing motions were filed ahead of the meeting, but the plan is certain to draw scrutiny from investors already nursing near-term losses.

Those losses were laid bare in the first-quarter numbers. Group revenue slumped 21.7% to €156.6 million, a figure that masks a still-uncomfortable 6% decline when stripping out currency effects and a one-off Sandoz licence payment in the prior year. The headline drop was driven by a weak market for early-stage drug discovery and the absence of that prior-year windfall. Restructuring provisions of €75 million under the Horizon programme pushed the operating result to minus €121.4 million, and the net loss landed at €121.9 million, or €0.69 per share. Cash and equivalents of €444.8 million provide a buffer, but the burn rate underscores the urgency of the turnaround.

Horizon itself is entering its execution phase. Evotec plans to consolidate its global footprint to ten sites, exit the Framingham facility in the US, and begin workforce adjustments in the third quarter. By the end of 2027, the programme is targeting structural annual savings of around €75 million, with 20% to 30% of that expected to materialise this year. The new chief operating officer, Dr. Ingrid Müller, joined in May to help drive implementation.

Should investors sell immediately? Or is it worth buying Evotec?

Against this backdrop of cost-cutting and operational pain, a rare bright spot emerged from the balance sheet. Evotec holds a 3.14% stake in Tubulis, a biotech being acquired by Gilead Sciences. The company expects upfront proceeds of roughly $100 million from that deal, with the potential for up to $58 million in additional milestone payments. For a group booking net losses and burning cash, that injection — even if booked as a one-off — provides welcome near-term liquidity and validates the strategic value of its equity holdings.

The board has also mandated Morgan Stanley and Moelis & Company to conduct a wide-ranging strategic review of the portfolio, capital structure, and long-term ownership setup. Evotec stresses that no transaction has been decided and no timeline is fixed, but the move adds another layer of uncertainty — and optionality — for a company in the midst of a multi-year transformation.

Management reaffirmed full-year guidance of €700 million to €780 million in revenue and adjusted EBITDA between zero and €40 million. The second half of 2026 is expected to show increasing evidence of operational improvement. Longer term, the ambition remains to cross €1 billion in sales and achieve EBITDA margins above 20% by 2030. A return to the MDAX index in June should boost visibility among institutional investors, though it does not alter the fundamental task of restoring organic growth.

Evotec at a turning point? This analysis reveals what investors need to know now.

Analysts are cautiously constructive: four rate the stock a buy, with a median price target near €7. That implies roughly 33% upside from current levels, but the path depends on how quickly Horizon delivers, whether the Tubulis proceeds arrive as expected, and whether the strategic review leads to portfolio moves that unlock further value. For now, Evotec presents two narratives in one — a restructuring story under pressure and a biotech portfolio that just delivered a significant payday. The AGM will test whether shareholders see the glass as half full or half empty.

Ad

Evotec Stock: New Analysis - 30 May

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

en | DE0005664809 | EVOTEC’S | boerse | 69446583 |